{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:32:13Z","timestamp":1767706333398,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Kidney transplant recipients are patients at high risk for coronavirus disease 2019 (COVID-19) due to being on immunosuppressive therapy. B cell depletion therapy, including rituximab, is an important strategy for ABO-incompatible transplants. However, knowledge about the effect of B cell depletion therapy on COVID-19 is lacking. Thirty kidney transplant recipients who developed COVID-19 were included in this study. To examine the impact of B cell depletion therapy, we retrospectively investigated the relationship between the background of the patients and the clinical outcome. Of the 30 patients, 13 received B cell depletion therapy. The median time between transplant and onset of COVID-19 was 6.1 years after transplantation; however, nine cases remained markedly depleted of CD19(+) cells (&lt;4.0%). The patients were assigned to the normal (n = 21) and depletion groups (n = 9). Progression rates in the depletion and normal groups were 55.6% and 9.5%, respectively (p = 0.014). Furthermore, the survival rate was significantly lower in the depletion group (100% in the normal group vs. 66.7% in the depletion group; p = 0.021). B cell depletion therapy may have long-term effects and increase the risk of COVID-19 in kidney transplant recipients.<\/jats:p>","DOI":"10.3390\/v15071520","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:45:37Z","timestamp":1688949937000},"page":"1520","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-4730","authenticated-orcid":false,"given":"Naohiro","family":"Aida","sequence":"first","affiliation":[{"name":"Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8423-2885","authenticated-orcid":false,"given":"Taihei","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2858","authenticated-orcid":false,"given":"Kei","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Hiratsuka","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-199X","authenticated-orcid":false,"given":"Atsushi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-8770","authenticated-orcid":false,"given":"Takashi","family":"Kenmochi","sequence":"additional","affiliation":[{"name":"Department of Transplantation and Regenerative Medicine, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2023, January 21). Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sandoval, M., Nguyen, D.T., Huang, H.J., Yi, S.G., Ghobrial, R.M., Gaber, A.O., and Graviss, E.A. (2022). COVID-19 mortality may be reduced among fully vaccinated solid organ transplant recipients. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0279222"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hardgrave, H., Wells, A., Nigh, J., Klutts, G., Krinock, D., Osborn, T., Bhusal, S., Rude, M.K., Burdine, L., and Giorgakis, E. (2022). COVID-19 Mortality in Vaccinated vs. unvaccinated Liver & Kidney Transplant Recipients: A Single-Center United States Propensity Score Matching Study on Historical Data. Vaccines, 10.","DOI":"10.3390\/vaccines10111921"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/ajt.17098","article-title":"Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge","volume":"22","author":"Radcliffe","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Montero, C., Torres, R., Benavidez, C., Garcia, P., Jimenez, S., Yomayusa, N., Gayon, D., Perez, J., Rosselli, D., and Restrepo, H. (2023). Impact of immunosuppression regimen on COVID-19 mortality in kidney transplant recipients: Analysis from a Colombian transplantation centers registry. Nefrolog\u00eda.","DOI":"10.1016\/j.nefroe.2022.09.006"},{"key":"ref_7","unstructured":"Japanese Society for Clinical Renal Transplantation (2022). The Japan Society for transplantation annual progress report from the Japanese Renal Transplant Registry: Number of renal transplantations in 2021 and follow-up survey. Ishoku, 57, 199\u2013219. (In Japanese)."},{"key":"ref_8","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection (2020). A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis., 20, e192\u2013e197."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497.x","article-title":"Pharmacodynamics of rituximab in kidney allotransplantation","volume":"6","author":"Genberg","year":"2006","journal-title":"Am. J. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.intimp.2013.02.025","article-title":"Combined standard and novel immunosuppressive substances affect B-lymphocyte function","volume":"15","author":"Matz","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0000000000003983","article-title":"The RECOVAC immune-response study: The immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant","volume":"106","author":"Sanders","year":"2022","journal-title":"Transplantation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e14790","DOI":"10.1111\/ctr.14790","article-title":"Immune response to third SARS-CoV-2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction","volume":"36","author":"Kantauskaite","year":"2022","journal-title":"Clin. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1397","DOI":"10.1097\/TXD.0000000000001397","article-title":"Predictors of nonseroconversion to SARS-CoV-2 vaccination in kidney transplant recipients","volume":"8","author":"Bouwmans","year":"2022","journal-title":"Transplant. Direct."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/TP.0000000000003922","article-title":"Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients","volume":"105","author":"Haskin","year":"2021","journal-title":"Transplantation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e226822","DOI":"10.1001\/jamanetworkopen.2022.6822","article-title":"Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: A systematic review and meta-analysis","volume":"5","author":"Manothummetha","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1050211","DOI":"10.3389\/fimmu.2022.1050211","article-title":"Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients","volume":"13","author":"Takai","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"152149","DOI":"10.1016\/j.semarthrit.2022.152149","article-title":"Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)","volume":"58","author":"Singh","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_20","first-page":"e32523","article-title":"Prolonged COVID-19 in a multiple sclerosis patient treated with rituximab","volume":"14","author":"Kintrilis","year":"2022","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2101334","DOI":"10.1080\/21645515.2022.2101334","article-title":"SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case","volume":"18","author":"Mukhina","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"848582","DOI":"10.3389\/fimmu.2022.848582","article-title":"Adaptive immune responses and immunity to SARS-CoV-2","volume":"13","author":"Primorac","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-022-04702-4","article-title":"Fc\u03b3R-mediated SARS-CoV-2 infection of monocytes activates inflammation","volume":"606","author":"Junqueira","year":"2022","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 Subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:08:14Z","timestamp":1760126894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["v15071520"],"URL":"https:\/\/doi.org\/10.3390\/v15071520","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}